Telix Pharmaceuticals (NASDAQ:TLX) Lowered to Sector Perform Rating by Royal Bank Of Canada

Royal Bank Of Canada cut shares of Telix Pharmaceuticals (NASDAQ:TLX) from an outperform rating to a sector perform rating in a report released on Friday morning, MarketBeat reports.

TLX has been the topic of several other research reports. Citigroup dropped their price objective on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Down 3.4%

Shares of Telix Pharmaceuticals stock opened at $10.46 on Friday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $16.94. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock has a 50-day moving average price of $10.36 and a 200 day moving average price of $9.06.

Insider Buying and Selling

In other news, CEO Christian Behrenbruch purchased 34,500 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were bought at an average price of $14.48 per share, with a total value of $499,560.00. Following the completion of the transaction, the chief executive officer directly owned 20,709,500 shares in the company, valued at $299,873,560. This trade represents a 0.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $975,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth $564,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the second quarter worth $213,000. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals during the third quarter worth $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.